Actual increase in biomarker testing in l

image: European Lung Cancer Congress 2022
to see Continued

Credit: ELCC organizers

Lugano, Switzerland, March 23, 2022 – More than half of patients diagnosed with advanced non-small cell lung cancer (NSCLC) undergo biomarker testing, and that number has been rising over the past five years, real data from a National Registry study reveals Spanish reported at the European Lung Cancer Congress (ELCC), March 30-April 2, 2022. The results of this study illustrate the value of registry data for improving lung cancer care. (1)

“The overall survival of lung cancer patients has increased by about 15% over the past decade, mainly because we now have new therapies, including targeted drugs. To use these therapies, we need to determine the molecular biomarkers on a patient’s tumor. Our study analyzed the rate of these molecular tests in real-world clinical practice,” explained lead author Dr. Virginia Calvo de Juan, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

The study assessed biomarker testing in the Thoracic Tumor Registry, an observational and prospective registry in Spain that included data for 9,239 patients diagnosed with stage IV NSCLC from 2016 to date. “Results showed that tumor biomarker testing was performed in 85% of patients with non-squamous tumors and 56.3% of those with squamous tumors, and this is important for making treatment decisions,” said Calvo de Juan. Almost half (44.5%) of patients undergoing testing had a positive result for EGFR, ALK, KRAS, BRAF, ROS1 or PDL-1.

Registry analysis showed a significant increase in all molecular tests in recent years. “The key message is that it is very important to have a registry to collect information about real cancer care. We can’t do better if we don’t have a clear idea of ​​what we are doing in routine clinical practice,” Calvo de Juan suggested. She noted that 182 hospitals across Spain participate in the chest tumor registry.

“The Spanish group is one of the best study groups in Europe and is very committed to providing targeted treatments for patients with lung cancer”, commented Professor Rolf Stahel, President of the European platform of thoracic oncology (ETOP). “Analysis of registry data shows a very high rate of molecular testing over a five-year period,” he said. He felt it would be useful to also look at how often molecular testing resulted in individual patients receiving appropriate targeted therapy.

“Cancer registries are very important for improving cancer patient outcomes for several reasons,” Stahel explained. “First, they can be useful in improving the quality of patient care.” A population-based or hospital-based registry collects patient data that can then be analyzed for particular aspects of cancer diagnosis, treatment, and outcomes. “You can then look at how a particular hospital or region is performing, compare yourself to other populations, and see where you are and how you can improve. Second, cancer registries can provide a way to study treatment effects in very rare cancers where there are too few patients to perform randomized trials.

ESMO has collaborated with the International Agency for Research on Cancer (IARC) and institutions to create a population-based lung cancer registry in Asian countries, including parts of Malaysia, Thailand, Indonesia and a clinical register in Singapore. The first question the registry analyzed was the proportion of patients with a pathological or clinical diagnosis, before looking at molecular testing for available targeted drugs. “The results were very heterogeneous between these countries,” Stahel noted. “The current step is to identify the gaps that drive variations in care and how healthcare providers can be supported to fill those gaps.” He concluded: “By supporting cancer registries, we can help support the spread of advances in cancer care across different regions to improve treatment and ensure that all patients can benefit.

-TO FINISH-

Notes to Editors

Please be sure to use the official name of the meeting in your reports: European Lung Cancer Congress 2022
Official congress hashtag: #ELCC22

Warning

This press release contains information provided by the author of the highlighted summary and reflects the content of that summary. It does not necessarily reflect the views or opinions of ELCC which cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with ESMO’s Declaration of Interests Policy and ESMO’s Code of Conduct.

The references

(1) Abstract 39P ‘Determination of essential biomarkers in lung cancer: a real-world data study in Spain’ will be available as an ePoster from Tuesday March 29, 2022 at 12:00 CEST. Annals of OncologyVolume 33 Supplement 2, April 2022

About the European Lung Cancer Congress
ELCC brings together some of the most important organizations in the field of thoracic oncology, with the aim of spreading education through a multidisciplinary approach and improving the practice of lung cancer specialists worldwide. ELCC is organized by ESMO (European Society of Medical Oncology) and IASLC (International Association for the Study of Lung Cancer), together with their partner societies ESTRO (European Society of Radiotherapy and Oncology), ESTS (European Society of Thoracic Surgeons) and ETOP IBCSG Partners Foundation (European Thoracic Oncology Platform and International Breast Cancer Study Group).

39P – Determination of essential biomarkers in lung cancer: a real-life data study in Spain.

V. Calvo de Juan1Mr Cobo Dols2D. Rodriguez-Abreu3E.Carcereny4A. Cantero5R. Bernabé Caro6G. Benítez Lopez3R. Lopez Castro7B. Massuti Sureda8E. del Barco9Mr. Garcia CampelotenMr. Guirado11CJC Camps Herrero12ALO Ortega Granados13JL Gonzalez-Larriba14A. Sanchez Hernandez15C. González Ojea16MA Sala Gonzalez17OJ Juan Vidal18Mr. Provencio Pulla1

1Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Majadahonda, Madrid, Spain, 2Medical Oncology, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, 3Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain, 4National and Kapodistrian University & Frontier Science Foundation Hellas, Athens, Greece, 5Oncología Médica., Hospital Regional Universitario Málaga Carlos Haya, Malaga, Spain, 6Medical oncology, Hospital Universitario Virgen del Rocio, Seville, Spain, 7Department of Radiotherapy and Medical Oncology, Hospital Clinico Universitario De Valladolid, Valladolid, Spain, 8Department of Medical Oncology, University General Hospital of Alicante, Alicante, Spain, 9ONcology, HOSP. CLINICO UNIVERSITARIO SALAMANCA, Salamanca, Spain, tenDepartment of Medical Oncology, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, 11Elche University General Hospital, Elche, Alicante, Spain, 12University General Hospital of Valencia, Valencia, Spain, 13Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Jaen, Spain, 14Department of Medical Oncology, Hospital Clinico Universitario San Carlos, Madrid, Spain, 15Department of Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellon De La Plana, Spain, 16Hospital Universitario Alvaro Cunqueiro, Vigo, Pontevedra, Spain, 17Basurto University Hospital, Bilbao, Spain, 18Department of Medical Oncology, Hospital Universitari i Politècnic La Fe, Valencia, Spain

context: The Thoracic Tumor Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumors from September 2016 to date. This TTR study was sponsored by the Spanish Lung Cancer Group Foundation (GECP), an independent, scientific and multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals throughout Spain.

Methods: Studying the situation of biomarker testing in Spain.

Results: 9,239 patients diagnosed with stage IV non-small cell lung cancer (NSCLC) were analyzed. 7467 (80.8%) were non-scaly and 1772 (19.2%) were scaly. Tumor marker testing was performed in 85.0% of patients with nonsquamous tumors versus 56.3% of those with squamous tumors (p-value

conclusion: Despite the absence of a national project and a standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing NGS in an integrated and cost-effective manner in lung cancer.

Identification of the clinical trial: NCT02941458

Legal entity responsible for the study: GECP FOUNDATION

Funding: Did not receive any funding

Disclosure: All authors have declared no conflict of interest.


Comments are closed.